Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27564899 | 0.86 | TDP1 (0.46) | KMT2AMAPTMEN1KDM4EGAA | |
| SCHEMBL28687501 | 0.78 | GPR35 (0.42) | KMT2AMAPTMEN1GAALMNA | |
| SCHEMBL27972715 | 0.76 | TSHR (0.37) | KMT2AMEN1KDM4EGAAL3MBTL1 | |
| SCHEMBL5202115 | 0.76 | KMT2A (0.44) | KMT2AMAPTMEN1KDM4EGAA | |
| SCHEMBL5674530 | 0.76 | KMT2A (0.41) | KMT2AMAPTMEN1KDM4EGAA | |
| SCHEMBL11493131 | 0.76 | KMT2A (0.41) | KMT2AMAPTMEN1KDM4EGAA | |
| SCHEMBL31598780 | 0.73 | CA2 (0.36) | CYP2C9 | |
| SCHEMBL28083530 | 0.73 | MAPK1 (0.41) | KMT2AMAPTMEN1GAAHTT | |
| SCHEMBL443597 | 0.73 | ALDH1A1 (0.43) | KMT2AMAPTMEN1KDM4EHTT | |
| SCHEMBL23136984 | 0.73 | PRKACA (0.45) | CYP3A4HTR2BKCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105585540-A | Preparation and application of novel Swern reagent | UNIV ZHEJIANG TECHNOLOGY | 2016-05-18 | — | — | CN | claimed |
| CN-113735879-B | Macrocyclic JAK inhibitor and application thereof | 百极弘烨（广东）医药科技有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-113583020-B | JAK2 inhibitor and application | 百极弘烨（广东）医药科技有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-113735879-A | Macrocyclic JAK inhibitor and application thereof | 百极弘烨(南通)医药科技有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-113583020-A | JAK2 inhibitor and application | 百极弘烨(南通)医药科技有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-105585540-A | Preparation and application of novel Swern reagent | UNIV ZHEJIANG TECHNOLOGY | 2016-05-18 | — | — | CN | disclosed |
| US-8242115-B2 | Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | KMT2A 1686/4885MAPT 4502/4885MEN1 2946/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | KMT2A 1686/4885MAPT 4502/4885MEN1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.